Base de données - (CIANE)

Présentation de cette base de données documentaires (site du CIANE)
Actuellement 3111 fiches
➡ Chaîne YouTube (tutoriel)

https://ciane.net/id=1961

Créée le : 19 Apr 2006
Modifiée le : 02 Dec 2007

➡ Modifier cette fiche
Ne suivez ce lien que si vous possédez un mot de passe d’éditeur !

Notice bibliographique (sans auteurs) :

Misoprostol for women’s health: a review. Review. {Afrique du Sud}. Obstet Gynecol. 2002 Feb;99(2):316-32.

Auteur·e(s) :

Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C.

Année de publication :

2002

URL(s) :

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=…

Résumé (français)  :

Abstract (English)  :

OBJECTIVE: To review published literature on misoprostol for women’s health indications to provide a synthesis of available information and highlight areas in need of additional research. DATA SOURCES: Studies were identified through searches of medical literature databases including MEDLINE, Cochrane Database, and Popline, in addition to a review of references from identified articles. STUDY SELECTION: We included all studies reported in English and published before March 31, 2001, which evaluated the efficacy of misoprostol alone for labor and delivery, evacuation of the uterus after pregnancy failure and induced abortion. Studies were not excluded based on quality or sample size. TABULATION, INTEGRATION, AND RESULTS: Misoprostol shows promise for all of the women’s health indications addressed. Currently available data, though, are often hard to interpret because of variations in regimen, dose, and outcome measures. The low cost, ease of administration and storage, and widespread availability of misoprostol make it particularly appealing for developing countries. Because many of the women’s health problems for which misoprostol could be prescribed currently cause significant mortality and morbidity, increased access to and information on use of misoprostol could help improve women’s health especially where these problems are most severe. CONCLUSION: Further research is needed to identify optimal regimens for misoprostol for obstetric and gynecologic health indications. Registering misoprostol with national drug regulatory authorities for any of several women’s health indications could help increase access to and safe use of this drug. Provider training would be a logical subsequent step.

Sumário (português)  :

Resumen (español)  :

Remarques :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Mots-clés :

➡ médecine factuelle ; déclenchement ; hémorragie postpartum ; misoprostol (Cytotec) ; dépassement de terme ; IVG interruption volontaire de grossesse, avortement

Auteur·e de cette fiche :

Cécile Loup — 19 Apr 2006
➡ dernière modification : Bernard Bel — 02 Dec 2007